Female Pattern Hair Loss (FPHL) is a very common condition that can seriously affect the quality of life of women. In-vitro investigations focusing on the essential role of stem cells in hair growth strongly suggest that the induction of hypoxia signaling pathway may play an important role in maintaining hair follicle stem cell function. A compound, pyridine-2, 4-dicarboxylic acid diethyl ester or Stemoxydine®, was identified in vitro as a competitive inhibitor of the Hypoxia-Inducible Transcription Factor (HIF-1alpha) hydroxylation and consequently an activator of the HIF-1alpha pathway. The efficacy of Stemoxydine® in increasing hair density was demonstrated in vehicle controlled clinical studies conducted on men with androgenetic alopecia (AGA). Further in-vitro assays revealed that associating Stemoxydine® to an antioxidant like Resveratrol could boost HIF-1alpha activity. The aim of this study was to evaluate the anti-hair loss performance of the association of 5% Stemoxydine® and 0.25% Resveratrol on women. 
Seventy nine healthy women aged 25 to 55 years old, presenting hair loss grade I to II according to the Ludwig scale, telogen hair count ≥ 18% and a total hair density between 150 and 400 hairs/cm² on test areas located in the vertex were recruited in the study.
After 6 weeks of daily topical application, a significant increase in total hair density (p=0.026) was observed on the area treated with the association Stemoxydine® + Resveratrol compared to a non-treated control area. This represents an increase of +4.6 hairs per cm² compared to control. This result was confirmed after 12 weeks of application, with a significant increase in total density compared to control was observed (+6.9 hairs/cm², p=0.008). Stemoxydine®/Resveratrol association thus appears as a novel option to improve hair density in women with FPHL.

A SPECIFIC ASSOCIATION TO MANAGE ALOPECIA IN WOMEN